Leap Therapeutics (LPTX): Rasio rega marang prakiraan pendapatan

LPTX (Leap Tx) - tandha merek perusahaan

High costs in the final stages of antibody testing are creating financial pressure on Leap Therapeutics, Inc. (LPTX). The forward P/S history indicates a support level where 96.40 reflects the metric's baseline. Patent protection of developments will ensure a stable margin, while current revenue is based on grants and licenses from partners in the gastrointestinal therapy sector.

LPTX Leap Tx: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 01.04.2023

Rincian analitis perusahaan Leap Therapeutics (LPTX)

- data kapitalisasi bursa:
Ringkesan analisis perusahaan:Leap Tx LPTX
Produk sing diprodhuksi leaptx.com

Forward P/S compares current market capitalization with projected revenue, reflecting investors' willingness to pay a premium for future income streams. For Leap Therapeutics, Inc. (LPTX), this indicator measures market optimism regarding the commercialization of targeted immunotherapy and the success of Phase II clinical trials, allowing for an assessment of the asset's fair value through the company's P/S expectations.

Analisis pesaing

ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Corp IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (arcusbio.com) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Biopharmaceuticals (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tango Pharma (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune)|Rega forward marang dodolan LYEL|innate-pharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology|Compugen Limited (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech, Inc. - Rega forward marang dodolan|STRO (sutrobio.com) - Multiplikator Forward P/S|Multiplikator Forward P/S MiNK Therapeutics Inc.|Rasio rega marang prakiraan pendapatan werewolftx.com (HOWL)|IMMX: Rega mangsa ngarep marang pendapatan|alxoncology.com - Multiplikator forward rega marang pendapatan|CUE - Multiplikator forward rega marang pendapatan|PDSB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Sonnet BioTherapeutics Holdings SONN|MAIA: Multiplikator Forward P/S|LIMN - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan LVTX|Kapitalisasi marang prakiraan pendapatan NXTC (NextCure)|Multiplikator Forward P/S INTS|Rasio kapitalisasi marang dodolan sing dikarepake Sensei Biotherapeutics, Inc.|Multiplikator Forward P/S TOVX (Theriva Corp)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP